Background: Novel immune checkpoint blockade strategies are being evaluated in clinical trials and include targeting the lymphocyte activation gene 3 (LAG-3) checkpoint, alone or in combination with PD-1/PD-L1 blockade. We investigated LAG-3 expression and its prognostic value in a large series of breast cancer patients, and correlated LAG-3 expression with key biomarkers including PD-1 and PD-L1.
Introduction
Although breast cancer is not generally considered an especially immunogenic malignancy in comparison to melanoma and lung cancer [1] , recent studies show that some tumors, especially estrogen receptor (ER)-negative breast cancers, do elicit an immune response [2] . Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), the programmed cell death receptor 1 (PD-1) and/or its ligand (PD-L1) have shown clinical efficacy, especially in melanoma and lung cancer [3, 4] . In breast cancer, results from early-phase trials have suggested checkpoint inhibitor efficacy may be primarily seen in triple-negative cases [5] . While the immuno-oncology field is moving at a fast pace, large-scale studies of immune checkpoint expression in breast cancer series are as yet few. The lymphocyte activation gene 3 (LAG-3) represents one example of a new immune checkpoint target.
LAG-3 is a cellular receptor expressed by activated T lymphocytes and is associated with T cell exhaustion [6] . LAG-3 is commonly upregulated with PD-1; pre-clinical data suggest that LAG-3 blockade releases T cells effector functions and synergizes with other immune checkpoint inhibitors such as anti-PD-1 [7] . Thus, LAG-3 represents an interesting target for immunotherapy and there are a number of ongoing early-phase clinical trials testing anti-LAG-3 therapeutic antibodies in different types of cancer. Our objective was to assess the prognostic value of LAG-3 and its association with PD-1 and PD-L1 immune checkpoints in a large, well-characterized cohort of breast cancer specimens.
Materials and methods

Study cohorts
The training set (used to finalize staining and scoring methodology) consisted of 330 invasive breast cancer cases from University of British Columbia hospitals diagnosed between 1989 and 2002 [8] . The validation set, previously described in detail [9] , consisted of 3992 female patients diagnosed with invasive breast cancer at the British Columbia Cancer Agency between 1986 and 1992. None of these patients received neoadjuvant treatment. Basic clinical and pathologic parameters of the study populations are summarized in Table 1 . The median follow-up time is 13 years for both sets. Access to the samples and corresponding de-identified outcome data was approved by the Clinical Research Ethics Board of the University of British Columbia and British Columbia Cancer Agency.
Immunohistochemistry
Formalin-fixed paraffin-embedded primary excision specimens were used to build tissue microarrays (TMA), represented as 0.6 mm cores as previously described [8, 10] . Biomarkers previously stained by immunohistochemistry (IHC) on the validation TMA include ER, PR, HER2, Ki67, EGFR, CK5/6, and CD8 [11] . IHC for LAG-3 and PD-1 was carried out using a Ventana Ultra automated stainer in accordance with manufacturer's protocol using the following antibodies and concentrations: LAG-3 (Clone 17B4, dilution 1 : 100, Abcam; see supplementary File S1, available at Annals of Oncology online), PD-1 (Clone NAT105, dispenser, Roche). PD-L1 staining was carried out at the Deeley Research Centre (Victoria, Canada) using clone SP142, dilution 1 : 100 (Spring Bioscience). Breast cancer intrinsic subtypes from both cohorts were previously determined by immunohistochemical methods that were originally developed against gene expression gold standards [12] . Briefly, Luminal A was defined as ERþ (!1%) or PRþ (!1%), HER2À and low Ki67, Luminal B as ERþ (or PRþ) and HER2þ or high Ki67 (!14%); HER2E as HER2þ and ERÀ and PRÀ; basal-like as HER2À/ERÀ/PRÀ with EGFRþ or CK5/6þ.
LAG-3, PD-1 and PD-L1 scoring
Biomarkers were evaluated and reported following REMARK guidelines [13] . TMA slides were digitally scanned and visually scored by an experienced pathologist blinded to clinical information. Scoring and quantification of LAG-3 and PD-1 were carried out as previously described for other lymphocyte biomarkers [9] . In brief, stromal lymphocytes were defined as lymphocytes not in direct contact with the breast carcinoma nest whereas intra-epithelial lymphocytes were located within the carcinoma nest. Scores of lymphocyte biomarkers were reported as absolute counts, and any positive expression (!1 TILs per TMA core) was used for dichotomization into positive and negative cases. PD-L1 scoring is a matter of controversy in the current literature; in this study, we used the method of McDermott et al. [14] whereby expression was assessed as the percentage of carcinoma cells with membranous expression; any cores with !1% of PD-L1þ carcinoma cells were considered positive. We found only 24 cases out of 2918 cases with PD-L1þ immune cells and they were discarded for further analyses. Cut-offs determined using the training set were locked down for analysis on the validation set.
Statistics
Statistical analyses were carried out using IBM SPSS (version 24.0) and R (version 3.3.2) software. Breast cancer-specific survival (BCSS) was the primary end point, defined as the time from date of diagnosis to date of death attributed to breast cancer. Patients who died from another cause or were alive at the end of follow-up were censored. Relapse-free survival (RFS) analyses were also carried out, defined as time from date of diagnosis to date of any type of breast cancer relapse (local, regional, distant or contralateral). Kaplan-Meier analysis, log-rank test and Cox proportional hazard regression models were used to evaluate correlation with survival. Multivariable Cox models were built to adjust the observed effect size and significance with clinicopathologic parameters (age, tumor grade and size, lymphovascular invasion status and nodal status). Findings observed on the training set, to be tested on the validation set, were prespecified in a formal written statistical plan, presented at the British Columbia Cancer Agency Breast Cancer Outcomes Unit. Additionally, for analyses of lymphocytes biomarker relationships, due to low numbers of positive cases in the training set, a training and validation approach was used by splitting the validation set in half. Findings to be validated on the other half of the set were prespecified in a written statistical plan before the analyses. All statistical tests carried out were twosided at a ¼ 0.05.
Results
Selection of LAG-31 TILs cut-offs on the training set
A total of 278 (84%) of breast cancer cases in the training set were interpretable for LAG-3 (supplementary Figure S1 , available at Annals of Oncology online). We found stromal lymphocytes expressing LAG-3 in 15% and intra-epithelial lymphocytes expressing LAG-3 in 14% of cases. As relatively few cases had LAG-3þ TILs in 0.3 mm 2 cores, any cases that had !1 lymphocyte expressing LAG-3 were deemed as positive. Both LAG-3þ sTILs and iTILs were significantly associated with negative prognostic factors including high-grade tumor, ER negativity and high Ki67 proliferation (supplementary Table S1 , available at Annals of Oncology online). Following our previous publications on lymphocyte biomarkers [9, 11] , we set on LAG-3þ iTILs ! 1/0.3 mm 2 core as our primary analysis for the validation set to allow comparison among lymphocyte biomarkers.
LAG-31 iTILs are enriched in ER2 subtypes and associated with improved survival
A total of 2921 (73%) cases were interpretable for LAG-3 staining on the validation set. LAG-3þ iTILs !1/0.3 mm 2 core were observed in 11% of breast cancer patients with a distribution range of 0-100 (Table 1 ). The presence of LAG-3þ iTILs was significantly associated with younger age, large tumor size, ER/PR negativity and high Ki67 proliferation index (Table 1; interaction  test by subtype shown in supplementary Table S2 , available at Annals of Oncology online). ERÀ tumor subtypes more commonly contained LAG-3þ iTILs, present in 33% of basal-like and 27% of HER2E samples (versus 3% and 11% in luminal A and luminal B tumor subtypes, respectively).
In the whole cohort and in the ERþ breast cancer subset (81% of cases), the presence of LAG-3þ iTILs was not significantly associated with survival ( Figure 1A and B) . In contrast, ERÀ breast cancer patients with LAG3þ iTILs had significantly improved breast cancer-specific survival and RFS, an association present in both HER2E and basal-like subtypes (Figure 1C to 1E ; supplementary Figure S2 , available at Annals of Oncology online). In multivariate analysis, LAG-3þ iTILs were a significant favorable prognostic factor in the whole cohort and among ERÀ breast cancer patients (supplementary Table S3A , available at Annals of Oncology online). Due to collinearity, the presence of LAG-3þ iTILs is not an independent prognostic factor in multivariate analyses that include CD8, PD-1 and PD-L1 as covariates (supple  mentary Table S3B , available at Annals of Oncology online); only PD-1þ iTILs represented a significant good prognostic factor in this model.
LAG-31 iTILs are strongly associated with PD-L1/ PD-11 tumors
Expression of immune checkpoint markers is regulated in a timedependent manner and can lead to cells expressing multiple immune checkpoint markers such as LAG-3 and PD-1 [6] . We investigated the association between tumors containing LAG-3þ TILs, PD-1þ TILs and carcinoma cells expressing PD-L1.
As expected, immune checkpoint markers were significantly associated with each other (Table 2 ) and with total stromal TIL levels (supplementary Table S4 , available at Annals of Oncology online); 53% of PD-L1þ tumors and 61% of tumors with PD-1þ TILs were also positive for LAG-3þ iTILs on equivalent-sized TMA cores, whereas only 38% of tumors with CD8þ iTILs were co-infiltrated with LAG-3þ TILs. The percentage of PD-L1þ tumors infiltrated with PD-1þ TILs was similar to that of LAG-3þ TILs but interestingly, only $20% of tumors with CD8þ iTILs had carcinoma cells positive for PD-L1 (Table 2 ). Scatter plots relating the investigated biomarkers are presented as supple mentary Figure S3 , available at Annals of Oncology online.
Exploratory analyses of concurrent tumor infiltration with LAG-31 and CD81 T cells
Given that LAG-3 can be expressed on different lymphocyte subsets (CD8 or CD4) [7] , we investigated the association between the presence of cytotoxic CD8þ iTILs and the prognostic value of LAG-3þ iTILs. In the absence of CD8þ iTILs, with relatively few cases positive for LAG-3, we found that the presence of LAG-3þ iTILs was no longer associated with survival among ERÀ breast cancer patients (Figure 2A ). In contrast, concurrent infiltration of LAG-3þ iTILs and CD8þ iTILs was significantly associated with better survival, suggesting an important role of CD8þ TILs expressing LAG-3 in breast cancer. Furthermore, we observed similar findings with concurrent infiltration of PD-1þ iTILs and CD8þ iTILs ( Figure 2B ; LAG-3 and PD-1 coinfiltration shown in supplementary Figure S4 , available at Annals of Oncology online). Surprisingly, in ERÀ breast cancer patients with no detectable CD8þ iTILs per 0.3 mm 2 core, the presence of PD-L1þ carcinoma cells was associated with a trend for poor BCSS, whereas patients with both CD8þ iTILs and PD-L1þ carcinoma cells had significantly improved BCSS ( Figure 2C ).
Discussion
In a large set of breast cancer patients, we report on the presence of an immune checkpoint biomarker targetable with new drugs. We found that LAG-3þ TILs can be scored quantitatively by IHC on TMA with consistent results supporting its analytical validity. By this methodology, LAG-3þ TILs are observed in a limited subset of patients (11%) that mostly fall into the HER2E and basallike breast cancer subtypes and is a favorable prognostic factor in ERÀ breast cancers. The presence of immune infiltrates most prominently in ERÀ breast cancers, detectable with lymphocyte biomarker assays, is now supported by a large body of evidence [2] .
In contrast, LAG-3þ iTILs were not prognostic in ERþ patients. This finding may not be surprising as ERþ breast cancers appear generally to be less immunogenic and have lower levels of TILs than ERÀ patients [2] . In the FinHER trial, the presence of TILs was not associated with survival in early-stage ERþ/HER2À breast cancer patients [15] , and in a combined analysis of two French Phase III clinical trials TILs were only prognostic in triple-negative and HER2-positive patients [16] .
High pretreatment serum levels of soluble LAG-3 have been associated with improved survival among ERþ breast cancer patients [17] . Soluble LAG-3 represents a splice variant with activating functions when bound to major histocompatibility complex II protein expressed on dendritic cells [18] . In contrast, our study measured the expression of LAG-3 on TILs in breast carcinoma tissues, and agrees with a recently published smaller study that found a subset of triple-negative breast cancers (TNBCs) had concurrent infiltration of LAG-3þ/PD-1þ TILs and that this was associated with a (non-significant) trend for improved survival [19] . In pre-clinical studies, LAG-3 expressing CD8þ TILs are exhausted and do not function properly, whereas LAG-3 expressing CD4þ regulatory T cells exhibit an enhanced immune suppressive function, supporting a hypothesis that the presence of LAG-3þ TILs in cancer patients should lead to poor survival. Instead, our results suggest that the presence of LAG-3 expressing TILs may in fact indicate that there is an ongoing cancer-immune interaction, a phenotype that is described as an inflamed tumor [20] and usually implies a somewhat improved prognosis. Indeed, we found that >50% of breast cancers that are PD-L1þ or are infiltrated with PD-1þ TILs have concurrent infiltration of LAG-3þ TILs.
In the training set cohort, we found that high levels of H&E sTILs (>50%, a level termed 'lymphocyte predominant breast cancer' or LPBC) correlated with increased co-infiltration of LAG-3þ/PD-1þ TILs. H&E sTILs are prognostic in ERÀ breast cancers and can be predictive of response to trastuzumab in HER2þ patients [15, 21] ; emerging evidence also suggests TIL count may predict response to anti-CTLA4 (ipilimumab) and anti-PD-1(pembrolizumab) [22, 23] . TIL counts carried out on H&E sections have the advantage of being applicable to existing slide sets or incident cases without requiring new immunohistochemical assays. However, this method necessarily combines all lymphocytes-including activating, suppressing and anergic populations, as well as NK and B cells. Theoretically, direct assessment of LAG-3 should be more likely to predict response to LAG-3-targeted checkpoint inhibitors; our study is a first step in defining an assessment method and a description of expression patterns over a large number of cases with detailed follow-up. The TMA format limits the capacity to directly compare with standardized H&E TIL scores [24] , and an assessment of the predictive capacity of LAG-3 in breast cancer will of course require application to randomized clinical trials.
The clinical activity of immune checkpoint inhibitors as single agents in breast cancer appears limited based on recent and varying results. In the KEYNOTE-012 trial of 32 women with advanced TNBC and !1% PD-L1 expression treated with pembrolizumab (a PD-1 inhibitor), the response rate was 18.5% [5] , with the median duration of response not yet reached at study publication. In a more recent presentation of 115 metastatic TNBC patients treated with atezolizumab (a PD-L1 inhibitor), a 10% overall response rate was seen irrespective of PD-L1 status, with most of this activity in the first-line setting [25] . The median progression-free survival was 1.4 months, but in those patients who achieved a response, the median duration of response was 21.1 months. Of note, in the exploratory biomarker analyses, there was a suggestion for better clinical outcomes in those tumors with higher levels of CD8þ T cell infiltrates. Lastly in a phase Ib study of previously taxane/anthracycline-treated, advanced breast cancer (N ¼ 168) treated with avelumab (a PD-L1 inhibitor), the response rate was only 4.8% in the overall population, and 8.6% in the TNBC cohort [26] .
It seems clear that the majority of advanced breast cancers do not achieve a response to single agent immune checkpoint 
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inhibition, although in the minority that do, the response appears relatively durable-as has been seen in other malignancies treated with these agents. The results of our study suggest considering stratification of patients in these clinical trials for both PD-1/PD-L1 status and LAG-3 status. As the field is now studying combinations of immune checkpoint inhibitors, our results raise the question whether the cohort of tumors with coexpression of PD-1/PD-L1 and LAG-3þ iTILs should be excluded from these trials as the natural history of this cohort is relatively favorable. Although this study has major strengths such as the use of analytically validated antibodies and multiple, large, well-annotated sets of breast cancer specimens, it also has some limitations. While long-term follow-up is a strength, the study cohort does date from a time before use of HER2 targeted therapies or of taxanes, which may affect extrapolation to contemporary patients. The breast cancer specimens used in the study were retrospectively collected and assembled into TMAs and as such, the area of the tumor analyzed reflects only a minute sampling of the original tumor tissue. In addition, co-infiltration of immune subsets (LAG-3þ, PD-1þ, CD8þ) had to be inferred from results of individually stained tissue sections and therefore cannot directly assess co-expression of immune checkpoints on the same cell.
In conclusion, LAG-3 is an immune checkpoint marker targeted by emerging treatments, and is most commonly expressed among ERÀ breast cancer patients-including in one-third of basal-like breast cancers, an aggressive subtype where checkpoint inhibitors have great promise and potential. Although our study does not directly measure biomarker expression in the metastatic setting, the strong association between tumors positive for PD-1/ PD-L1þ and LAG-3þ biomarkers suggests a potential for the combination of therapies targeting these immune checkpoint markers, a concept currently being evaluated in clinical trials in metastatic disease [27] .
